Related Experiment Videos
Bone pain palliation with 85Sr therapy
F Giammarile1, T Mognetti, C Blondet
1Nuclear Medicine Department, Centre Léon Bérard, Lyon, France.
Summary
Strontium-85 (85Sr) effectively palliates metastatic bone pain, offering significant pain relief and improved quality of life for many patients. Early-stage disease and prostate cancer patients showed the best outcomes with this radionuclide therapy.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiopharmacology
Background:
- Metastatic bone pain significantly impacts patient quality of life.
- Palliative care options for refractory bone pain are crucial.
- Radionuclide therapy offers a systemic approach to pain management.
Purpose of the Study:
- To evaluate the efficacy of Strontium-85 (85Sr) in palliating metastatic bone pain.
- To assess the safety and tolerability of 85Sr therapy.
- To identify patient subgroups that benefit most from 85Sr treatment.
Main Methods:
- Retrospective study analyzing data from 108 patients treated between 1977 and 1992.
- Intravenous administration of 85Sr chloride (mean activity 335 MBq).
- Evaluation of pain, performance status, blood counts, and survival post-treatment.
Main Results:
- 72.2% of patients experienced significant pain relief and improved quality of life at 12 weeks.
- 49.1% of patients became completely pain-free, with benefits lasting a mean of 4.3 months.
- Prostate cancer patients and those with early-stage metastatic disease showed the best response.
Conclusions:
- Systemic radionuclide therapy with 85Sr is a feasible and effective palliative treatment for refractory bone pain.
- 85Sr therapy achieved comparable response rates to other bone-seeking radionuclides like 89Sr.
- Optimal patient selection, particularly early-stage disease and prostate cancer, enhances treatment outcomes.